Piramal Pharma shares are up on getting US FDA EIR for US plant, inspection closed successfullyPiramal Pharma shares are up on getting US FDA EIR for US plant, inspection closed successfully

Introduction

Leading pharmaceutical company has received US FDA Establishment Inspection Report for its Lexington facility, marking inspection closure with Voluntary Action Indicated classification.

Also Read: WSFx Global Pay rolls out UNI-Z card for seamless international fee payments, stock price up 6%

Share price movement of Piramal Pharma

On April 13, 2026, Piramal Pharma Ltd opened at ₹144.15, down 1.33% from its previous close of ₹146.10. The stock reached a high of ₹147.45 (0.92%) and a low of ₹140.85. By 11:51 AM, it traded at ₹146.85, a 0.51% increase, with a market cap of ₹19,520.01 crore.

Piramal Pharma FDA Inspection Closed

Piramal Pharma Limited has received an Establishment Inspection Report from the US FDA for its Lexington, Kentucky manufacturing facility. The inspection has been officially closed.

The US FDA issued a Voluntary Action Indicated classification in the report. The company stated that receipt of the EIR marks successful closure of the inspection process.

Stock performance of Piramal Pharma for period of 1 week, 6 months, and 1 year

Piramal Pharma Ltd delivered a 1-week return of 3.14%, a 6-month return of -24.6%, and a 1-year return of -33.6%.

Also Read: RailTel share price moves up 4% after winning ₹23.18 Cr order to build Goa welfare portal

Shareholding pattern of Piramal Pharma

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	34.90%	34.90%	34.90%
FII	29.70%	30.30%	30.90%
DII	15.70%	14.90%	14.30%
Public	19.40%	19.50%	19.50%
Others	0.50%	0.50%	0.60%

About Piramal Pharma

Piramal Pharma Ltd (NSE: PPLPHARMA) is part of Piramal Group, operating in CDMO, hospital generics, and consumer healthcare, built through acquisitions and organic growth initiatives.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs